Autosomal polycystic kidney disease (ADPKD) is the most common form of inherited kidney disease. The international guideline developer, Kidney Disease: Improving Global Outcomes (KDIGO), published a 2025 clinical practice guideline reflecting advances in genetic testing and the first disease-modifying agent, tolvaptan. However, KDIGO guidelines do not address healthcare access or equity issues relevant to the needs of our populations in Australia and New Zealand. The Caring for Australians and New ZealandeRs with kidney Impairment (CARI) Guidelines Working Group has provided a regional commentary to contextualise the KDIGO 2025 ADPKD guideline. This commentary aims to support clinicians in applying the KDIGO ADPKD 2025 guidance within our local health systems and highlights challenges in the implementation, including public subsidy limitations for recommended genetic testing and treatments. It also addresses equity concerns such as rural and remoteness, ensuring guidance is relevant to Australia and New Zealand.
Abdy et al. (Tue,) studied this question.